30,000€
0,67%
Echtzeit-Aktienkurs CymaBay Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der CymaBay Therapeutics Inc. Aktie
Börsenkurse CymaBay Therapeutics Inc.
Fundamentaldaten der CymaBay Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 31,07 Mio. | -105,37 Mio. | -105,37 Mio. | -0,99 | - | - | 109,93 |
| 2022 [USD] | - | -106,00 Mio. | -106,00 Mio. | -1,21 | - | - | - |
| 2021 [USD] | - | -90,00 Mio. | -90,00 Mio. | -1,27 | - | - | - |
| 2020 [USD] | - | -50,99 Mio. | -50,99 Mio. | -0,74 | - | - | - |
| 2019 [USD] | - | -102,81 Mio. | -102,81 Mio. | -1,53 | - | - | - |
| 2018 [USD] | - | -72,55 Mio. | -72,55 Mio. | -1,26 | - | - | - |
| 2017 [USD] | 10,00 Mio. | -27,56 Mio. | -27,56 Mio. | -0,79 | - | - | 133,23 |
| 2016 [USD] | - | -26,67 Mio. | -26,67 Mio. | -1,14 | - | - | - |
| 2015 [USD] | - | -15,53 Mio. | -15,53 Mio. | -0,83 | - | - | - |
| 2014 [USD] | - | -31,92 Mio. | -31,92 Mio. | -2,65 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der CymaBay Therapeutics Inc. Aktie
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique